Exploring the protective association between COVID-19 infection and laryngeal cancer: insights from a Mendelian randomization study

Front Immunol. 2024 Jun 10:15:1380982. doi: 10.3389/fimmu.2024.1380982. eCollection 2024.

Abstract

Introduction: Viral infections have been implicated as a risk factor for laryngeal cancer. Given the possible effects of Corona virus disease 2019 (COVID-19) on the laryngeal tissue, we investigated the causal link between COVID-19 and laryngeal cancer using a two-sample Mendelian randomization (MR) approach.

Methods: We utilized genetic data from the 5th Genome-wide association studies (GWAS) edition of the COVID-19 Host Genetics Initiative (published on January 18, 2021) and a large-scale laryngeal cancer GWAS comprising 180 cases and 218,612 controls of European ancestry. We applied inverse variance weighting, MR Egger, and weighted median methods to infer causality. We performed sensitivity analysis using the "leave-one-out" method to verify robustness.

Results: We found no evidence of a causal association between gene-predicted COVID-19 and laryngeal cancer [Odds ratio (OR)=0.24 (95% Confidence intervals (CI), 0.05-1.26), P=0.09]. However, we observed significant inverse associations between gene-predicted COVID-19 hospitalization [OR=0.51 (95% CI, 0.28-0.95), P=0.03] and severe patients [OR=0.62 (95% CI, 0.43-0.90), P=0.01] and laryngeal cancer. Notably, the study detected important genetic variants, such as rs13050728, that modulate the expression of interferon alpha receptor 2 (IFNAR2), indicating possible roles for immune response pathways in both COVID-19 and cancer.

Discussion: This study reveals a potential interaction between COVID-19 severity, genetic factors, and laryngeal cancer, underscoring the importance of investigating the immune response mechanisms in both conditions. These findings contribute to the understanding of the complex interactions between COVID-19 and laryngeal cancer and may guide future research on the role of immune response, particularly involving IFNAR2.

Keywords: COVID-19; IFNAR2; Mendelian randomization; immune response; laryngeal cancer; viral infections.

MeSH terms

  • COVID-19* / genetics
  • COVID-19* / immunology
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study*
  • Humans
  • Laryngeal Neoplasms* / genetics
  • Laryngeal Neoplasms* / immunology
  • Laryngeal Neoplasms* / virology
  • Mendelian Randomization Analysis*
  • Polymorphism, Single Nucleotide*
  • Risk Factors
  • SARS-CoV-2* / physiology

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study received funding from the General Program of the National Natural Science Foundation of China (No. 82071031).